http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106518971-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 |
| filingDate | 2016-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106518971-B |
| titleOfInvention | Anti-obesity decapeptide CANPHELPNK |
| abstract | The invention discloses an anti-obesity decapeptide CANPHELPNK, the amino acid sequence of the polypeptide is shown as follows: Cys-Ala-Asn-Pro-His-Glu-Leu-Pro-Asn-Lys, abbreviated CANPHELPNK, molecular weight 1122.27, purity 97.55%. The polypeptide of the invention is synthesized by a solid phase synthesis method by using a polypeptide synthesizer. Through in vitro mouse preadipocyte 3T3-L1 proliferation inhibition activity detection, the polypeptide of the invention has certain inhibition effect on 3T3-L1 within the range of 0.125-2 mg/mL. The in vitro proliferation inhibition rate of 3T3-L1 at 2 mg/mL was 59.51%. The invention provides a synthetic polypeptide with potential in vitro anti-obesity activity, which can be applied to the field of biological pharmacy. |
| priorityDate | 2016-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.